Sign up to save your podcasts
Or
Share Tulisokibart, a New Drug for Moderate-to-Severe UC That May Come With Personalized Medicine
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Tulisokibart, a New Drug for Moderate-to-Severe UC That May Come With Personalized Medicine
Ellen Axenfeld, MD and Elie Al Zazzi, MD, MPH discuss "Phase 2 Trial of Anti-TL1A Monoclonal Antibody Tulisokibart for Ulcerative Colitis,” by Sands BE, Feagan BG, Peyrin-Biroulet L, et al and the ARTEMIS-UC Study Group. Published in N Engl J Med. 2024 Sep 26;391(12):1119-1129.
View all episodes
By American College of Gastroenterology
4.8
1616 ratings
Ellen Axenfeld, MD and Elie Al Zazzi, MD, MPH discuss "Phase 2 Trial of Anti-TL1A Monoclonal Antibody Tulisokibart for Ulcerative Colitis,” by Sands BE, Feagan BG, Peyrin-Biroulet L, et al and the ARTEMIS-UC Study Group. Published in N Engl J Med. 2024 Sep 26;391(12):1119-1129.
More shows like Evidence-Based GI: An ACG Publication and Podcast
View all
Gut Podcast
7 Listeners
NEJM This Week
314 Listeners
American Journal of Gastroenterology Author Podcasts
72 Listeners
JAMA Clinical Reviews
489 Listeners
The Curbsiders Internal Medicine Podcast
3,318 Listeners
Core IM | Internal Medicine Podcast
1,108 Listeners
The Peter Attia Drive
8,007 Listeners
Annals On Call Podcast
191 Listeners
The Clinical Problem Solvers
512 Listeners
Harrison's PodClass: Internal Medicine Cases and Board Prep
349 Listeners
Behind the Case: An ACG Case Reports Journal Podcast
6 Listeners
The Lancet Gastroenterology & Hepatology in conversation with
0 Listeners
Listen In: GI Endoscopy
33 Listeners
Gastroenterology Learning Network
10 Listeners
Gastroenterology & Endoscopy
3 Listeners